Paper Details

  1. Home
  2. Paper Details

Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.

Author: Hidalgo-VegaAlvaro, Ramos-GoñiJuan Manuel, VilloroRenata

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ranolazine, a medication for chest pain (angina), is used for patients whose angina is not well controlled or who cannot tolerate standard medications. The study notes that these patients often experience a significant decline in quality of life due to frequent angina episodes, which can also increase the risk of needing more invasive treatments like bypass surgery.
Paper Details　
Original Abstract of the Article :
Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal therapies. These patients' quality of life is significantly affec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10198-013-0534-8

データ提供：米国国立医学図書館（NLM）

Cost-Utility of Ranolazine for Chronic Angina Pectoris

This research explores the cost-effectiveness of ranolazine, an antianginal agent, for treating chronic angina pectoris in Spain. The researchers analyzed the cost-utility of ranolazine compared to other treatment options for patients with chronic angina pectoris. They found that ranolazine was a cost-effective treatment option, improving quality of life and reducing the need for revascularization procedures.

Ranolazine: A Cost-Effective Treatment for Angina

The study suggests that ranolazine is a viable and cost-effective treatment option for chronic angina pectoris. It highlights the potential for ranolazine to improve quality of life for patients experiencing angina, while also reducing the need for expensive revascularization procedures.

Managing Angina Pectoris

Patients with angina pectoris should discuss treatment options with their healthcare provider. They can work together to develop a personalized treatment plan that considers individual factors, such as the severity of angina, overall health, and medication preferences. This study underscores the importance of considering cost-effectiveness in evaluating treatment options for chronic diseases.

Dr.Camel's Conclusion

This research, like a camel carrying essential supplies through a challenging desert, explores the cost-effectiveness of ranolazine for treating angina. It suggests that this medication can provide relief from angina symptoms and potentially save on healthcare costs in the long run, demonstrating the importance of balancing treatment efficacy with financial considerations.

Date :
  1. Date Completed 2015-07-20
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

24122303

DOI: Digital Object Identifier

10.1007/s10198-013-0534-8

Related Literature

Article Analysis
・Effective treatment of angina
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.